Related Experiment Video
Updated: Mar 16, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics
L Cornmark1, C Holmgren1, K Masoumi1
1Department of Laboratory Medicine, Translational Cancer Research, Lund University , Lund, Sweden.
Abstract:
There is a need for novel strategies to initiate cancer cell death. One approach is the use of Smac mimetics, which antagonize inhibitor of apoptosis proteins (IAPs). Recent studies have shown that combinations of Smac mimetics such as LBW242 or LCL161 in combination with chemotherapeutic agents increase cancer cell death. Here we show that the protein kinase C (PKC) activator TPA together with the Smac mimetic LBW242 induces cell death in two basal breast cancer cell lines (MDA-MB-468 and BT-549) that are resistant to Smac mimetic as single agent. Ten other LBW242-insensitive cancer cell lines were not influenced by the TPA+LBW242 combination. The TPA+LBW242 effect was suppressed by the PKC inhibitor GF109203X, indicating dependence on PKC enzymatic activity. The PKC effect was mediated via increased synthesis and release of TNFα, which can induce death in the presence of Smac mimetics. The cell death, coinciding with caspase-3 cleavage, was suppressed by caspase inhibition and preceded by the association of RIP1 with caspase-8, as seen in complex II formation. Smac mimetics, but not TPA, induced the non-canonical NF-κB pathway in both MDA-MB-231 and MDA-MB-468 cells. Blocking the canonical NF-κB pathway suppressed TPA induction of TNFα in MDA-MB-468 cells whereas isolated downregulation of either the canonical or non-canonical pathways did not abolish the Smac mimetic induction of the NF-κB driven genes TNFα and BIRC3 in MDA-MB-231 cells although the absolute levels were suppressed. A combined downregulation of the canonical and non-canonical pathways further suppressed TNFα levels and inhibited Smac mimetic-mediated cell death. Our data suggest that in certain basal breast cancer cell lines co-treatment of TPA with a Smac mimetic induces cell death highlighting the potential of using these pathways as molecular targets for basal-like breast cancers.
Insights
Combining protein kinase C (PKC) activator TPA with Smac mimetic LBW242 induces cancer cell death in resistant basal breast cancer cells. This targeted approach offers potential for new basal-like breast cancer therapies.
Area of Science:
- Molecular Oncology
- Cancer Cell Death Induction
- Signal Transduction Pathways
Background:
- Novel strategies are needed to induce cancer cell death, as current treatments face resistance.
- Smac mimetics, which target inhibitor of apoptosis proteins (IAPs), show promise in combination therapies.
- Basal breast cancer cell lines often exhibit resistance to single-agent Smac mimetics.
Purpose of the Study:
- To investigate the efficacy of combining a protein kinase C (PKC) activator (TPA) with a Smac mimetic (LBW242) in inducing cell death.
- To explore the underlying molecular mechanisms, including the roles of PKC, TNFα, and NF-κB pathways.
- To identify potential therapeutic targets for basal-like breast cancers.
Main Methods:
- Treatment of basal breast cancer cell lines (MDA-MB-468, BT-549) with TPA and LBW242.
- Assessment of cell death induction, PKC activity, TNFα synthesis, and caspase cleavage.
- Analysis of RIP1/caspase-8 complex formation and NF-κB pathway activation (canonical and non-canonical).
Main Results:
- TPA plus LBW242 induced cell death in LBW242-resistant MDA-MB-468 and BT-549 cells.
- The effect was dependent on PKC activity and mediated by TNFα, involving caspase-3 cleavage and RIP1/caspase-8 complex formation.
- Combined inhibition of canonical and non-canonical NF-κB pathways suppressed TNFα and cell death, suggesting a role in this combination therapy.
Conclusions:
- Co-treatment with TPA and a Smac mimetic is a viable strategy to induce cell death in specific basal breast cancer cell lines.
- The combination therapy leverages PKC activation, TNFα production, and caspase-dependent cell death pathways.
- Targeting these pathways presents a promising therapeutic avenue for basal-like breast cancers.
More Related Videos
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway
Mitogens and the Cell Cycle